Document is current
Any future updates will be listed below
-
Authors
Ruhrberg Estévez, Silas
Baltusyte, Greta
Youssef, Gehad
Han, Namshik
-
Funding
Funding for this research was provided by:
National Research Council of Science and Technology (GTL24021-000)
LifeArc grant (RG91966)
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 1 December 2025
First Online: 9 February 2026
Competing interests
: N.H. is the co-founder and Chief Technology Officer of CardiaTec Bio, a company developing therapeutics for cardiovascular diseases, and the co-founder of KURE.ai, which focuses on AI-driven oncology drug discovery. N.H. also serves on the Scientific Advisory Board of the Institute of Cancer Research (ICR). These affiliations are unrelated to the subject matter of this manuscript.
